FibroGenFGEN
About: FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Employees: 486
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
11.32% less ownership
Funds ownership: 57.07% [Q2] → 45.75% (-11.32%) [Q3]
15% less call options, than puts
Call options by funds: $248K | Put options by funds: $291K
29% less funds holding
Funds holding: 102 [Q2] → 72 (-30) [Q3]
61% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 33
63% less capital invested
Capital invested by funds: $50.7M [Q2] → $18.9M (-$31.8M) [Q3]
81% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 37
Research analyst outlook
We haven’t received any recent analyst ratings for FGEN.
Financial journalist opinion
